Source: Annual Congress 2002 - The role of inflammatory markers in children with asthma
Disease area: Airway diseases

Abstract

Introduction: T-cell activation appears to be a characteristic feature of Inflammation in asthma. In patients with acute asthma who respond well to bronchodilator therapy, the main mechanism of airflow obstruction is smooth muscle contraction, while in patients with poor response the main mechanism is airway inflammation.
Methods: Sixty children with acute asthma exacerbation divided into three groups (Mild, Moderate, & Severe) depending on a clinical scoring system and on measurig Peak Expiratory Flow Rate (PEFR) and Oxygen Saturation were included in this study. Serum level of sIL-2R was measured using enzyme-linked immunosorbent assay both in the studied patients and in 20 healthy controls.
Results: Mean serum level of sIL-2R in the studied cases (5207.5+2084.9 pg/ml) was significantly higher than its mean level in controls (1742.5+801.9 pg/ml) ( t=9.37 P=<0.0001). Its mean level in severe exacerbation (8090.8+1222.6 pg/ml) was significantly higher than its mean level in moderate exacerbation (5255.0+1112.8 pg/ml), that was significantly higher than its mean level in mild exacerbation (3164.6+990.8 pg/ml) ( F= 77.36 P=<0.0001). There was a significant negative correlation between the levels of sIL-2R and both the baseline PEFR ( r = -0.710 P=<0.0001 ) and Oxygen saturation ( r = -0.521 P=<0.0001). After receiving bronchodilator therapy, the mean level of sIL-2R in cases with no or partial response (6486.8+ 1900.4 pg/ml) was significantly higher than its mean level in cases with complete response (4088.1+1534.9 pg/ml) ( t=5.406 P=<0.0001).
Conclusion: A higher level of sIL-2R at acute asthma exacerbation was associated not only with more severe exacerbation but also with a lower degree of bronchodilator responsiveness.

Rating:

Share or cite this content

Citations should be made in the following way:
Z. M. Hussein, O. M. Badr-Eldin, M. M. Eissa, H. A. Elmetwally, G. M. El-Derini (Alexandria, Egypt). Serum level of soluble interleukin-2 receptors (sIL-2R) during acute asthma exacerbation, and its relation to severity and response to bronchodilator therapy. Eur Respir J 2002; 20: Suppl. 38, 919

Member's Comments

No comment yet.

Related content which might interest you: The relationship between serum soluble interleukin-2 receptor levels and disease severity in sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 355s Year: 2006 Serum interleukin-6 levels correlate with malnutrition in patients with acute exacerbation of COPD Source: Annual Congress 2009 - Organisation of care for individuals with chronic respiratory disease Year: 2009 The effect of montelukast and triamcinolon on clinical parameters and serum levels of ECP, sIL-2R and IL-4 in children with moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 123s Year: 2001 Effect of systemic steroid treatment on serum leptin levels in patients with COPD exacerbation Source: Eur Respir J 2005; 26: Suppl. 49, 284s Year: 2005 Increased serum endotoxin levels as biomarker in acute exacerbations of COPD. Source: International Congress 2018 – Biomarkers of COPD Year: 2018 Plasma biomarkers and response to therapy at exacerbation of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 39s Year: 2007 Serum levels of IL-6 in adult patients with moderate to severe asthma. Source: International Congress 2017 – Novel mechanisms in asthma Year: 2017 Serum YKL-40 modulation in severe asthma patients treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Serum soluble ST2 is corticosteroid sensitive in asthma Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010 Elevated serum IL-12 and IL-18 levels in patients with bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 424s Year: 2002 Interleukin-10 (IL-10) level in sputum of asthmatic patients during exacerbation and after treatment Source: Eur Respir J 2001; 18: Suppl. 33, 336s Year: 2001 The assesment of serum TNFα levels in COPD acute exacerbation and the effects of inhaler steroids on clinical and inflammatory determinants Source: Eur Respir J 2002; 20: Suppl. 38, 312s Year: 2002 Activin-A levels in sputum and serum of COPD, asthma and ACOS patients during acute exacerbation and at baseline Source: International Congress 2017 – Infection and exacerbation science Year: 2017 Cytokines concentrations in induced sputum of mild COPD patients. Correlation to clinical response to inhaled corticosteroids Source: Eur Respir J 2002; 20: Suppl. 38, 309s Year: 2002 Serum TNF-a, IL-12 and IL-13 levels in severe bronchial asthma patients Source: Eur Respir J 2004; 24: Suppl. 48, 353s Year: 2004 Change of induced sputum TNF-a and sTNF-R55,75 levels in patients with acute exacerbations of COPD Source: Annual Congress 2007 - Respiratory pathophysiology Year: 2007 Relationship between systemic IFNγ and IL5 levels and exacerbation frequency in COPD Source: Eur Respir J 2001; 18: Suppl. 33, 153s Year: 2001 Clinical value of soluble interleukine-2 receptor (sIL-2R) serum level examination in the pulmonary sarcoidosis (PS) Source: Eur Respir J 2003; 22: Suppl. 45, 226s Year: 2003 Serum levels of IL-8, IL-10 and TNFα in severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 279s Year: 2005 The effects of inhaled steroids, leukotriene receptor antagonists and theophylline on induced sputum cell counts, serum and sputum ECP levels in mild persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001